Table 1 Patient characteristics in the subgroups with or without cardiac amyloidosis (CA)
From: Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance
All n = 206 | CA n = 107 (52%) | No CA n = 99 (48%) | *p-value | |
|---|---|---|---|---|
Age (years) | 76 (69–81) | 76 (69–81) | 73 (65–79) | 0.178 |
Male sex (n, %) | 137 (67) | 79 (74) | 58 (59) | 0.021 |
BSA (m2) | 1.84 (1.74–1.96) | 1.84 (1.72–1.94) | 1.85 (1.75–2.01) | 0.399 |
CMR findings | ||||
LVEDVI (mL/m2) | 79 (67–96) | 79 (67–92) | 81 (67–97) | 0.153 |
LVESVI (mL/m2) | 33 (23–50) | 31 (24–46) | 36 (22–56) | 0.445 |
LVSVI (mL/m2) | 44 (37–51) | 43 (36–51) | 45 (39–51) | 0.192 |
LVEF (%) | 55 (46–67) | 57 (46–65) | 55 (44–67) | 0.625 |
CO (L/min) | 5.3 (4.3–6.6) | 5.3 (4.3–6.5) | 5.2 (4.4–6.7) | 0.752 |
LVMI (g/m2) | 84 (71–111) | 95 (77–118) | 73 (64–98) | < 0.001 |
LA area index (cm2/m2) | 16 (13–18) | 17 (14–18) | 14 (12–18) | 0.008 |
RA area index (cm2/m2) | 13 (11–15) | 14 (12–16) | 12 (10–14) | < 0.001 |
RVEDVI (mL/m2) | 70 (57–81) | 74 (60–83) | 63 (55–77) | 0.013 |
RVESVI (mL/m2) | 28 (20–37) | 32 (22–41) | 24 (18–32) | < 0.001 |
RVSVI (mL/m2) | 39 (33–47) | 38 (32–43) | 41 (36–49) | 0.087 |
RVEF (%) | 59 (47–65) | 54 (44–63) | 61 (57–68) | < 0.001 |
Early bloodpool darkening (n, %) | 40 (19) | 39 (36) | 1 (1) | < 0.001 |
LGE presence (n, %) | 174 (84) | 105 (98) | 69 (69) | < 0.001 |
LGE subendocardial-to-transmural pattern (n, %) | 89 (43) | 85 (79) | 4 (4) | < 0.001 |
Pericardial effusion (n, %) | 48 (23) | 30 (28) | 18 (18) | 0.087 |
Pleural effusion (n, %) | 58 (28) | 45 (42) | 13 (13) | < 0.001 |